FDA Orange Book · active-ingredient family
Diatrizoate meglumine; diatrizoate sodium
Diatrizoate meglumine; diatrizoate sodium is approved as 4 brand and 11 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:MD-76R · NDA 019292
4
Brand (NDA)
11
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · injectable, solution
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| MD-76RRLD | LIEBEL-FLARSHEIM | NDA 019292 | — | Sep 29, 1989 | |
| RENOGRAFIN-76RLD×4 | BRACCO | NDA 010040 | — | Approved Prior to Jan 1, 1982 | |
| GASTROGRAFINRLD | BRACCO | NDA 011245 | AA | Approved Prior to Jan 1, 1982 | |
| HYPAQUE-M,75%×2 | GE HEALTHCARE | NDA 010220 | — | Approved Prior to Jan 1, 1982 |
Generic (ANDA) products (11)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM | ANNORA PHARMA | ANDA 215049 | AA | Nov 17, 2023 | |
| DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM | ANDA REPOSITORY | ANDA 214201 | AA | Jun 27, 2022 | |
| RENOCAL-76 | BRACCO | ANDA 089347 | — | Jun 01, 1988 | |
| DIATRIZOATE-60 | INTL MEDICATION | ANDA 088166 | — | Jun 17, 1983 | |
| ANGIOVIST 292 | BAYER HLTHCARE | ANDA 087724 | — | Sep 23, 1982 | |
| ANGIOVIST 370 | BAYER HLTHCARE | ANDA 087723 | — | Sep 23, 1982 | |
| GASTROVIST | BAYER HLTHCARE | ANDA 087728 | — | Sep 23, 1982 | |
| HYPAQUE-76 | GE HEALTHCARE | ANDA 086505 | — | Approved Prior to Jan 1, 1982 | |
| MD-60 | MALLINCKRODT | ANDA 087074 | — | Approved Prior to Jan 1, 1982 | |
| MD-76 | MALLINCKRODT | ANDA 087073 | — | Approved Prior to Jan 1, 1982 | |
| MD-GASTROVIEW | LIEBEL-FLARSHEIM | ANDA 087388 | AA | Approved Prior to Jan 1, 1982 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Diatrizoate meglumine; diatrizoate sodium — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

